ER-REBOA PLUS™ Catheter Earns UK and CE Mark Approval USA - PRNewswire

-

BOERNE, Texas, May 24, 2021 /PRNewswire/ -- Prytime Medical Devices, Inc. announced today it has received both UK and CE Mark Approval for its next-generation ER-REBOA PLUS™ Catheter. Designed for improved ease of use, this catheter replaces the market defining ER-REBOA™ catheter and represents an important evolution of REBOA technology. The new catheter is REBOA Refined for controlling non-compressible truncal hemorrhage.

"With this milestone, the new and improved ER-REBOA PLUS™ Catheter will now be available for patients in the UK and Europe in addition to our previous approvals in the US and Canada," said Andrew Holman, CCO at Prytime Medical. "REBOA interest in the global trauma community continues to grow, so we work hard to continue to bring industry best solutions to physicians world-wide. We are pleased the next-generation ER-REBOA PLUS™ Catheter is available to our expanding global community of users."

The ER-REBOA PLUS™ Catheter maintains all the critical features of its namesake predecessor, including the only integrated arterial line for monitoring above-balloon blood pressure available on the market, industry leading on-label guidewire free and image free placement, low-profile 7Fr sheath compatibility, and patented atraumatic P-tip™ to aid in positioning. Important new features of the ER-REBOA PLUS™ include a pre-captured balloon for ease of use, dual-sided length and zone markers, and a "leave behind" guidewire capability up to 0.025" to support transition to subsequent endovascular procedures.

"UK and CE Mark approval for ER-REBOA PLUS™ is another important milestone for Prytime Medical," said David Spencer, CEO, Prytime Medical. "Our mission is to deliver state of the art minimally invasive solutions for hemorrhage control, so we will continue to innovate and expand access to our life-saving technology around the world."

To learn more about Prytime Medical™ and the ER-REBOA PLUS™ Catheter, visit www.prytimemedical.com, email [email protected] or call +1 (210) 340-0116.

About Prytime Medical Devices, Inc.
Prytime Medical™ Devices, Inc. is an innovative medical device company that designs, develops, and commercializes minimally invasive solutions for hemorrhage control. In trauma, hemorrhage is the leading cause of potentially survivable death. Non-compressible truncal hemorrhage is of particular interest, because of the limited clinical options available to stop bleeding prior to surgery. The underlying intellectual property for the original ER-REBOA™ technology was conceived by experienced military vascular surgeons, based on lessons learned in war. The new ER-REBOA™ PLUS Catheter represents an important evolution of REBOA and includes several new convenience features based on experience and input from civilian trauma surgeons from around the world.

SOURCE Prytime Medical

Related Links

https://www.prytimemedical.com

Comments

Post a Comment

Popular posts from this blog

Well-liked Medicare plan vs. higher-ranked providers - ChicagoNow

-
Image
Medicare Open Enrollment ends December 7. The easy choice is to stay with all-in-one Medicare Advantage instead of switching to Traditional Medicare plus a supplement and drug plan. The hard one is whether to switch between Medicare Advantage plans, from a well-liked one to one accepted at a so-called top-10 hospital. Humana Gold Plus, a Medicare Advantage HMO, has served me well for five years. Hearing aids cost me only $10 after its $2,000 allowance. Routine doctor and dentist appointments and my medication cost nothing. But Humana Gold Plus is not accepted by Northwestern Memorial Hospital, the nearby hospital that US News & World Report ranks as the tenth best in the country, or by Northwestern Medicine physicians. My primary care physician is in an Advocate Medical Group. If I were hospitalized, it would be at Advocate Illinois Masonic Medical Center. If I had a serious illness, I’d see specialists in Advocate’s network. Illinois Masonic is not a second-rate hospital, and...
Read more

Minnesota veterans blame 3M's 'defective' ear plugs for hearing damage - KSTP

-
Image
3M did not admit any wrongdoing as part of that settlement. Read 3M's full statement on the ear plugs here. "We deny this product was defectively designed," a company spokesperson said in a statement to 5 INVESTIGATES, adding they will "defend against the allegations in these lawsuits." More than 630 lawsuits have been filed and will be heard in a federal court in Florida. An attorney involved with the multi-district litigation says roughly 30 have been filed by veterans who live in Minnesota. Constant ringing Sarah Kay Carlson, an Army veteran from St. Paul, filed her lawsuit in April, claiming 3M exposed her and thousands of other Marines and soldiers to "extremely dangerous and disabling noise." 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (PDF) 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (Text) Carlson, who was deployed as part of Operation Iraqi Freedom in the late 2000s, provided security to convoys t...
Read more

Sickle Cell Disease (SCD): Practice Essentials, Background, Genetics

-
Image
hemophilia c factor 11 :: Article Creator Regeneron Reports Fourth Quarter And Full Year 2023 Financial And Operating Results Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenuesincreased 14% Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022;excluding Ronapreve(a), revenuesincreased 12% Fourth quarter 2023 Dupixent®global net sales(recorded by Sanofi) increased 31% to $3.22 billion versus fourth quarter 2022; full year 2023 Dupixent global net sales increased 33% to $11.59 billion versus 2022 Fourth quarter 2023 U.S. Net sales for EYLEA®HD and EYLEA®were $1.46 billion, including $123 million from EYLEA HD; full year 2023 U.S. Net sales for EYLEA HD and EYLEA were $5.89 billion, including $166 million from EYLEA HD following its August 2023 FDA approval Fourth quarter 2023 Libtayo®global n...
Read more